InMed Pharmaceuticals Inc. (INM) discloses COO stock option expiration

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc.'s Chief Operating Officer, as a single reporting person, filed a Form 4 detailing an insider derivatives transaction with the company.

On 12/15/2025, an employee stock option labeled as an expiration and linked to 60 common shares was reported, with a US$1,397.97 exercise price, converted from a C$1,925.00 exercise price using an exchange rate of C$1.3770 = $US1.00. After this transaction, 7,445 derivative securities were reported as beneficially owned on a direct basis.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WOUDENBERG MICHAEL

(Last) (First) (Middle)

C/O INMED PHARMACEUTICALS INC.

1445-885 WEST GEORGIA ST.

(Street)

VANCOUVER A1 V6C3E8

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ INM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Expiration)	$1,397.97(1)	12/15/2025		H			60	12/16/2020	12/15/2025	Common shares	60	$0.00	7,445	D

Explanation of Responses:

1. Converted from the Canadian dollar exercise price of C$1,925.00 using an exchange rate of C$1.3770 = $US1.00

	/s/ Eric A. Adams, attorney-in-fact for Mr. Michael Woudenberg	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did InMed Pharmaceuticals Inc. (INM) report in this Form 4?

The filing reports an employee stock option expiration on 12/15/2025, involving a derivative security tied to 60 common shares of InMed Pharmaceuticals Inc.

Who is the reporting person in the InMed (INM) Form 4 and what is their role?

The reporting person is identified as an officer of InMed Pharmaceuticals Inc., with the title Chief Operating Officer, filing the form as one reporting person.

What was the exercise price of the employee stock option reported for InMed (INM)?

The employee stock option had a US$1,397.97 exercise price, which was converted from a C$1,925.00 exercise price using an exchange rate of C$1.3770 = $US1.00.

How many shares underlay the employee stock option in the InMed (INM) Form 4?

The derivative security described as an employee stock option was linked to 60 common shares of InMed Pharmaceuticals Inc. as the underlying security.

How many derivative securities does the InMed (INM) officer own after the reported transaction?

Following the reported option expiration, the officer reported 7,445 derivative securities as beneficially owned on a direct ownership basis.

Does the InMed (INM) Form 4 include any non-derivative securities transactions?

The provided tables show details only in Table II for derivative securities, with no entries populated in Table I for non-derivative securities.